Texas Medication Algorithm Project, Phase 3 (TMAP-3): Clinical results for patients with a history of mania

被引:77
作者
Suppes, T [1 ]
Rush, AJ
Dennehy, EB
Crismon, ML
Kashner, TM
Toprac, MG
Carmody, TJ
Brown, ES
Biggs, MM
Shores-Wilson, K
Witte, BP
Trivedi, MH
Miller, AL
Altshuler, KZ
Shon, SP
机构
[1] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA
[2] Univ Texas, Coll Pharm, Pharm Practice & Adm, Austin, TX 78712 USA
[3] Texas Dept Mental Hlth & Mental Retardat, Austin, TX USA
[4] Univ Texas, SW Med Ctr, Dept Vet Affairs, Htlh Serv Res & Dev Serv Res Career Scientist Pro, Dallas, TX USA
关键词
D O I
10.4088/JCP.v64n0403
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background The Texas Medication Algorithm Project (TMAP) assessed the clinical and economic impact of algorithm-driven treatment (ALGO) as compared with treatment-as-usual (TAU) in patients served in public mental health centers. This report presents clinical outcomes in patients with a history of mania (BD), including bipolar I and schizoaffective disorder, bipolar type, during 12 months of treatment beginning March 1998 and ending with the final active patient visit in April 2000. Method Patients were diagnosed with bipolar I disorder or schizoaffective disorder, bipolar type, according to DSM-IV criteria. ALGO was comprised of a medication algorithm and manual to guide treatment decisions. Physicians and clinical coordinators received training and expert consultation throughout the project. ALGO also provided a disorder-specific patient and family education package. TAU clinics had no exposure to the medication algorithms. Quarterly outcome evaluations were obtained by independent raters. Hierarchical linear modeling, based on a declining effects model, was used to assess clinical outcome of ALGO versus TAU. Results: ALGO and TAU patients showed significant initial decreases in symptoms (p = .93 and p < .001, respectively) measured by the 24-item Brief Psychiatric Rating Scale (BPRS-24) at the 3-month assessment interval, with significantly greater effects for the ALGO group. Limited catch-up by TAU was observed over the remaining 3 quarters. Differences were also observed in measures of mania and psychosis but not in depression, side-effect burden, or functioning. Conclusion: For patients with a history of mania, relative to TAU, the ALGO intervention package was associated with greater initial and sustained improvement on the primary clinical outcome measure, the BPRS-24, and the secondary outcome measure, the Clinician-Administered Rating Scale for Mania (CARS-M). Further research is planned to clarify which elements of the ALGO package contributed to this between-group difference.
引用
收藏
页码:370 / 382
页数:15
相关论文
共 65 条
[1]   THE CLINICIAN-ADMINISTERED RATING-SCALE FOR MANIA (CARS-M) - DEVELOPMENT, RELIABILITY, AND VALIDITY [J].
ALTMAN, EG ;
HEDEKER, DR ;
JANICAK, PG ;
PETERSON, JL ;
DAVIS, JM .
BIOLOGICAL PSYCHIATRY, 1994, 36 (02) :124-134
[2]  
[Anonymous], 1994, Am J Psychiatry, V151, P1
[3]  
[Anonymous], 1992, HIERARCHICAL LINEAR
[4]  
BAUER MS, 1991, ARCH GEN PSYCHIAT, V48, P807
[5]   Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs [J].
Bauer, MS ;
Callahan, AM ;
Jampala, C ;
Petty, F ;
Sajatovic, M ;
Schaefer, V ;
Wittlin, B ;
Powell, BJ .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (01) :9-+
[6]   Principles of effectiveness trials and their implementation in VA cooperative study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder' [J].
Bauer, MS ;
Williford, WO ;
Dawson, EE ;
Akiskal, HS ;
Altshuler, L ;
Fye, C ;
Gelenberg, A ;
Glick, H ;
Kinosian, B ;
Sajatovic, M .
JOURNAL OF AFFECTIVE DISORDERS, 2001, 67 (1-3) :61-78
[7]   The Internal State Scale: replication of its discriminating abilities in a multisite, public sector sample [J].
Bauer, MS ;
Vojta, C ;
Kinosian, B ;
Altshuler, L ;
Glick, H .
BIPOLAR DISORDERS, 2000, 2 (04) :340-346
[8]  
Bero LA, 1998, BMJ-BRIT MED J, V317, P465
[9]   A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder [J].
Bowden, CL ;
Calabrese, JR ;
McElroy, SL ;
Gyulai, L ;
Wassef, A ;
Petty, F ;
Pope, HG ;
Chou, JCY ;
Keck, PE ;
Rhodes, LJ ;
Swann, AC ;
Hirschfeld, RMA ;
Wozniak, PJ .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (05) :481-489
[10]  
Bowden CL, 1997, PSYCHOPHARMACOL BULL, V33, P693